This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ABSTRACT Background Atrialfibrillation and atrialflutter are relatively rare in young people and the incidence of thromboembolic complications is unknown. These issues contribute to the limited utility of present guidelines regarding anticoagulation in this population.
Atrialfibrillation (AF) is the most common sustained arrhythmia and associated with increased morbidity and mortality. PubMed was queried for entries on AF and rurality: (atrialfibrillation OR atrialflutter) AND (rural OR urban OR rurality OR metro OR metropolitan) AND (united states OR US OR U.S.)
Although atrialfibrillation/atrialflutter (AFib/AFL) are common manifestations of transthyretin amyloid cardiomyopathy (ATTR-CM), a post hoc analysis of the ATTR-ACT study, published April 30 in JACC: CardioOncology, found they do not predict all-cause mortality.
Here is the computer interpretation: ATRIALFIBRILLATION WITH RAPID VENTRICULAR RESPONSE WITH ABERRANT CONDUCTION OR VENTRICULAR PREMATURE COMPLEXES LEFT AXIS DEVIATION [QRS AXIS beyone -30] NONSPECIFIC ST and T-WAVE ABNORMALITY The over-reading physician confirmed this diagnosis, which is incorrect. It is not atrialfibrillation.
Abstract Introduction The use of flecainide and propafenone for medical cardioversion of atrialfibrillation (AF) and atrialflutter/intra-atrial reentrant tachycardia (IART) is well-described in adults without congenital heart disease (CHD).
FAAM ablation successfully decreased the recurrence rate of atrial tachyarrhythmia compared with conventional non-PV foci ablation. Abstract Introduction Treatment of recurrent atrialfibrillation (AF) is sometimes challenging due to non-pulmonary vein (PV) foci. The RHYTHMIA system was used to perform all the procedures.
Although the QDOT MICRO™ Catheter was mainly designed for pulmonary vein isolation (PVI) its versatility to treat atrialfibrillation (AF) and other types of arrhythmias was recently evaluated by the FAST and FURIOUS study series and other studies and will be presented in this article.
She also has a hx of paroxysmal atrialfibrillation and is on oral anticoagulant treatment. The ECG was interpreted as showing atrialflutter with 2:1 conduction. The heart rate could be compatible with that of a 2:1 conducted atrialflutter. The last echocardiography 12 months ago showed HFmrEF.
Intravenous (IV) digoxin loading dose recommendations for rate control of atrial arrhythmias in critically ill patients are not well studied. Intravenous (IV) digoxin loading dose recommendations for rate control of atrial arrhythmias in critically ill patients are not well studied. ng/mL is recommended. ng/mL is recommended.
It is atrialflutter with 2:1 conduction. There are clear flutter waves in lead II across the bottom. In V1, there are upright waves that appear to be P-waves but are not: they are atrial waves and it is typical for atrialflutter waves to be upright in V1, whereas sinus P-waves are biphasic in V1.
ABSTRACT Introduction The safety and efficacy of paroxysmal atrialfibrillation (PAF) ablation with the HELIOSTAR multielectrode radiofrequency (RF) balloon catheter have been demonstrated in European studies; data from elsewhere are lacking. Central Illustration. Image is courtesy of Biosense Webster, Inc., All rights reserved.
Abstract Background Dofetilide is a class III antiarrhythmic agent approved for the treatment of atrialfibrillation and atrialflutter. Given the efficacy of other class III agents, it has been used off-label for the treatment of premature ventricular complexes (PVCs) and ventricular tachycardias (VTs).
Procedures were most commonly for atrialfibrillation (52.4%), atrialflutter (10.9%), and atrioventricular nodal re-entrant tachycardia (10.1%). Results 1089 patients were included: MC 718 (65.9%); Fo8 HT 105 (9.6%); Fo8 MOD 266 (24.4%). 01; minor: MC 16.5%, Fo8 HT 12.0%, Fo8 MOD 7.4%, p =.002).
There is atrial activity before every QRS, but that activity has negative polarity, so it is not sinus rhythm. There are clearly no flutter waves, so it is not atrialflutter (a "macro-reentrant" atrial tachycardia) Is it AVNRT originating at the superior pole of the AV node, resulting in a retrograde P-wave before the QRS?
ABSTRACT Background Different ablation strategies have been developed for persistent atrialfibrillation (PeAF), but early management is still controversial. In the clinical setting of PeAF, the safety and efficacy of early Marshall plan have not yet been fully studied.
Annotated Bibliography For an excellent overview of ED Syncope management , see this article by Kessler C et al. starts at end of article on p. DATA SOURCES: Studies were identified through a MEDLINE search (1980 to present) and a manual review of bibliographies of identified articles. Commentary by Heidenreich PA.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content